News

Press Releases

December 15, 2021

Novita Pharmaceuticals Doses First Patient in Phase 1B-2A Clinical Study of NP-G2-044 in Patients with Advanced or Metastatic Solid Tumor Malignancies

Read More

July 28, 2021

Novita Pharmaceuticals and China Resources Double Crane Pharmaceutical Enter into an Exclusive License Agreement to Develop and Commercialize Fascin Inhibitor in China

Read More

May 20, 2021

Novita Pharmaceuticals to Present its Fascin Inhibitor NP-G2-044 Phase 1A Results in Patients with Advanced and Metastatic Solid Tumors at 2021 ASCO Annual Meeting

Read More

Novita Pharmaceuticals, Inc

Suite 19A

445 Park Avenue

New York, NY 10022

© 2023 Novita Pharmaceuticals, Inc. | Site Design by Digital Elevator